AIM To explore the clinical effects of sacubitril valsartan on heart failure patients with mid-range ejection fraction.
METHODS Eighty-two patients with heart failure with mid-range ejection fraction (HFmrEF), who were treated in the Department of Cardiology, Xijing Hospital, Air Force Medical University from December 2018 to June 2019, were randomly divided into a control group and a research group, 41 cases in each group. Based on general treatment, the control group was given 80 mg valsartan orally twice a day, while the research group was given 100 mg sacubitril valsartan orally twice a day. The therapeutic effects and the incidence of adverse events of the two groups were compared.
RESULTS Before treatment, there was no statistical difference in baseline data between two groups. After treatment, compared with the control group, the treatment effective rate of patients in research group was significantly enhanced with statistical significance (P < 0.05). Compared with those before treatment, there were significant differences in left ventricular ejection fraction (LVEF), left ventricular overall longitudinal strain (LVGLS) and left ventricular short axis shortening rate (FS) in both groups (P < 0.05). After treatment, LVGLS in the research group was higher than that in control group, with statistical significance (P < 0.05). The levels of GDF-15, sST2 and NT-proBNP in heart failure related markers were significantly different from those before treatment in the same group (P < 0.05) and the improvement of GDF-15 and NT-proBNP in the research group was more obvious than that in the control group (P < 0.05). Compared with those before treatment, there were significant differences in the 6 min walking distance (6MWD) and the Minnesota heart failure scale score (MHFQL) in both groups (P < 0.05). After treatment, there was no significant difference in the 6MWD between the two groups. The MHFQL in research group was significantly lower than that in control group, with statistical significance (P < 0.05). There was no significant difference in the incidence of cardiovascular events, readmission rate and mortality rate between the two groups.
CONCLUSION With no significant difference in the incidence rate of cardiovascular events, readmission rate and mortality rate, the effect of sacubitril valsartan is more significant than valsartan for treatment of cardiac functions in patients with heart failure with mid-range ejection fraction, which is worthy of additional research and clinical consideration.
DownLoad: